◆英語タイトル:Xbrane Biopharma AB (XBRANE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8091
◆発行会社(調査会社):
GlobalData
◆発行日:2018年10月
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Xbrane Biopharma AB (Xbrane), formerly Xbrane Bioscience AB is a biopharmaceutical company that develops and manufactures complex generic products. The company’s product portfolio includes biosimilars and long acting injectables developed for people suffering from critical diseases. It combines its proprietary microsphere and protein production technology platforms to develop and produce generics drugs for controlled release of the active substance through encapsulation in microspheres. The company’s products find application in treating diseases across various therapeutic areas including acromegaly and neuroendocrine tumours, prostate cancer, endometriosis and uterine fibroids; age-related macular degeneration and macular oedema, among others. Xbrane is headquartered in Stockholm, Sweden.
Xbrane Biopharma AB (XBRANE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Xbrane Biopharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Xbrane Biopharma and STADA Arzneimittel Enter into Co-Development Agreement 10
Xbrane Biopharma to Enter into Distribution Agreement for Spherotide in China 11
XBrane Biopharma Enters into Distribution Agreement with Helvetic BioPharma for Xlucane 12
Xbrane Bioscience Enters into Distribution Agreement with Pooyesh Darou Pharma 13
Licensing Agreements 14
China Resources Pharma Enters into Licensing Agreement with Xbrane Biopharma 14
China Resources Pharma to Enter into Licensing Agreement with Xbrane Biopharma 15
BioAvenir Enters into Licensing Agreement with Xbrane Biopharma 16
Equity Offering 17
Xbrane Biopharma Raises USD2.3 Million in Private Placement of Shares 17
Xbrane Biopharma Raises USD11.6 Million in Rights Offering of Shares 19
Acquisition 20
Xbrane Bioscience Acquires Primm Pharma 20
Xbrane Biopharma AB – Key Competitors 21
Xbrane Biopharma AB – Key Employees 22
Xbrane Biopharma AB – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 24, 2018: Xbrane Biopharma releases interim report for the second quarter of 2018 24
May 14, 2018: Xbrane Biopharma Releases Interim Report for the First Quarter of 2018 25
Feb 28, 2018: Xbrane Biopharma releases year-end report for 2017 26
Nov 13, 2017: Xbrane Biopharma releases interim report for the period July to September 2017 27
Aug 31, 2017: Xbrane Biopharma Releases Interim Report for the Period April – June 2017 28
May 18, 2017: Xbrane Biopharma releases interim report for the period January – March 2017 29
Feb 27, 2017: Xbrane Biopharma releases 2016 Year End Report 30
Corporate Communications 31
Dec 13, 2017: Xbrane Biopharma informs about changes in management team 31
May 04, 2017: Xbrane Biopharma recruits CFO and Head of Investor Relations 32
Product News 33
Sep 10, 2018: Xbrane Biopharma announces product portfolio update with a new full strategic focus on biosimilars 33
Apr 11, 2017: Xbrane Biopharma Reports Positive In-vivo Efficacy Data On Spherotide 34
Mar 27, 2017: Xbrane Biopharma Delivers First Batch Of Spherotide To A Value Of 7 Msek 35
Other Significant Developments 36
May 24, 2018: Announcement from Xbrane Biopharma’s annual general meeting 36
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38
List of Tables
Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Xbrane Biopharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Xbrane Biopharma AB, Deals By Therapy Area, 2012 to YTD 2018 8
Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Xbrane Biopharma and STADA Arzneimittel Enter into Co-Development Agreement 10
Xbrane Biopharma to Enter into Distribution Agreement for Spherotide in China 11
XBrane Biopharma Enters into Distribution Agreement with Helvetic BioPharma for Xlucane 12
Xbrane Bioscience Enters into Distribution Agreement with Pooyesh Darou Pharma 13
China Resources Pharma Enters into Licensing Agreement with Xbrane Biopharma 14
China Resources Pharma to Enter into Licensing Agreement with Xbrane Biopharma 15
BioAvenir Enters into Licensing Agreement with Xbrane Biopharma 16
Xbrane Biopharma Raises USD2.3 Million in Private Placement of Shares 17
Xbrane Biopharma Raises USD11.6 Million in Rights Offering of Shares 19
Xbrane Bioscience Acquires Primm Pharma 20
Xbrane Biopharma AB, Key Competitors 21
Xbrane Biopharma AB, Key Employees 22
Xbrane Biopharma AB, Subsidiaries 23
List of Figures
Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Xbrane Biopharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8